** Shares of vaccine maker Moderna MRNA.O fall 6.1% to $26.81
** Co pushes back the time frame for likely approval of a combination vaccine meant to protect against both COVID-19 and influenza
** "It's not directly clear how MRNA will be impacted by HHS (Department of Health and Human Services) requirements for placebo studies for "new" vaccines... Flu will not need placebo per HHS. But overall, changes by HHS bring uncertainty for the landscape and investors" - brokerage Jefferies
** MRNA posts Q1 adj loss of $2.52/shr, smaller than Wall Street estimates for a loss of $3.14/shr - LSEG
** Co brings in $108 mln in Q1 revenue, slightly ahead of analysts' expectations of $106.2 mln
** Including session's move, stock down 33.9% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.